Literature DB >> 17362866

Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss.

Jennifer E Thorne1, Fasika Woreta, Sanjay R Kedhar, James P Dunn, Douglas A Jabs.   

Abstract

PURPOSE: To estimate the incidences of ocular complications and vision loss in patients with juvenile idiopathic arthritis (JIA)-associated uveitis, to describe risk factors for vision loss, and to describe the association between therapy and complications and vision loss.
DESIGN: Retrospective cohort study.
METHODS: setting: Single-center, academic practice. study population: A total of 75 patients with JIA-associated uveitis evaluated between July 1984 and August 2005. procedures: Clinical data on these patients were analyzed. outcome measures: Occurrence of ocular complications and visions of 20/50 or worse and 20/200 or worse.
RESULTS: Over a median follow-up of three years, the incidence of any ocular complication was 0.33/eye-year (EY). Rates of vision loss to 20/50 or worse and 20/200 or worse were 0.10/EY and 0.08/EY, respectively. Risk factors at presentation for incident vision loss included presence of posterior synechiae, anterior chamber flare > or = 1+, and abnormal intraocular pressure (IOP). During follow-up, ocular inflammation > or = 0.5+ cells was associated with an increased risk of visual impairment (relative risk [RR] = 2.02, P = .006) and of blindness (RR = 2.99, P = .03). Immunosuppressive drug therapy reduced the risk of hypotony by 74% (P = .002), epiretinal membrane formation by 86% (P = .05), and blindness in the better eye by 60% (P = .04).
CONCLUSIONS: Incident vision loss and complications were common. Presence of posterior synechiae, anterior chamber flare > or = 1+, and abnormal IOP at presentation were associated with vision loss during follow-up. Use of immunosuppressive drugs reduced the risk of some ocular complications and of blindness in the better-seeing eye.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362866     DOI: 10.1016/j.ajo.2007.01.033

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  63 in total

Review 1.  [Uveitis in juvenile idiopathic arthritis].

Authors:  C Heinz; A Heiligenhaus; J Kümmerle-Deschner; I Foeldvari
Journal:  Z Rheumatol       Date:  2010-07       Impact factor: 1.372

2.  Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Authors:  H Nida Sen; Lea T Drye; Debra A Goldstein; Theresa A Larson; Pauline T Merrill; Peter R Pavan; John D Sheppard; Alyce Burke; Sunil K Srivastava; Douglas A Jabs
Journal:  Ocul Immunol Inflamm       Date:  2012-04       Impact factor: 3.070

Review 3.  Juvenile idiopathic arthritis-associated uveitis.

Authors:  Ying Qian; Nisha R Acharya
Journal:  Curr Opin Ophthalmol       Date:  2010-11       Impact factor: 3.761

4.  Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis.

Authors:  Allison R Loh; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2010-10       Impact factor: 5.258

Review 5.  Uveitis in juvenile idiopathic arthritis.

Authors:  Arnd Heiligenhaus; Kirsten Minden; Dirk Föll; Uwe Pleyer
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

Review 6.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

7.  Development of a vision-related quality of life instrument for children ages 8-18 years for use in juvenile idiopathic arthritis-associated uveitis.

Authors:  Sheila T Angeles-Han; Kenneth W Griffin; Melanie J Harrison; Thomas J A Lehman; Traci Leong; Rachel Reeves Robb; Marla Shainberg; Lori Ponder; Phoebe Lenhart; Amy Hutchinson; Sunil K Srivastava; Sampath Prahalad; Scott R Lambert; Carolyn Drews-Botsch
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

Review 8.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

9.  Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.

Authors:  Courtney McCracken; Steven Yeh; Kirsten Jenkins; Curtis Travers; Daneka Stryker; Steven Tommasello; Kelly A Rouster-Stevens; Scott R Lambert; Sampath Prahalad; Carolyn Drews-Botsch; Sheila T Angeles-Han
Journal:  Eye (Lond)       Date:  2018-11-28       Impact factor: 3.775

10.  Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.

Authors:  Anthony C Gregory; John H Kempen; Ebenezer Daniel; R Oktay Kaçmaz; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2012-10-11       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.